Summary
This Form 8-K filing from Beigene, Ltd. (ONC) reports on the presentation of updated and initial clinical data from several ongoing Phase 1b trials at the 59th American Society of Hematology (ASH) Annual Meeting. The data pertains to the company's investigational Bruton's Tyrosine Kinase (BTK) inhibitor, zanubrutinib (BGB-3111), in various combinations and patient populations. Key presentations included zanubrutinib in combination with GAZYVA® (obinutuzumab) for chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma, zanubrutinib alone for non-Hodgkin's lymphoma, and zanubrutinib combined with Beigene's own investigational anti-PD-1 antibody, tislelizumab (BGB-A317), for B-cell malignancies. These presentations offer investors a glimpse into the early-stage development and potential efficacy of Beigene's pipeline candidates.
Key Highlights
- 1Beigene presented updated preliminary clinical data from a Phase 1b trial of zanubrutinib (BGB-3111) combined with GAZYVA® (obinutuzumab) in patients with CLL/SLL and follicular lymphoma at ASH.
- 2Preliminary clinical data from a Phase 1b trial of zanubrutinib (BGB-3111) in patients with non-Hodgkin’s lymphoma was also presented at ASH.
- 3Initial data from a Phase 1b trial combining zanubrutinib (BGB-3111) with Beigene's investigational anti-PD-1 antibody, tislelizumab (BGB-A317), in B-cell malignancies was presented.
- 4All presented data is from ongoing Phase 1b clinical trials, indicating early-stage development.
- 5The presentations occurred at the 59th American Society of Hematology (ASH) Annual Meeting.
- 6Zanubrutinib is being evaluated in multiple hematological indications and combinations.
- 7The filings consist of three press releases detailing the presented data.